PRA

3Q 2021 CORPORATE UPDATE

November 2021

Forward-looking statements

This presentation may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and financial conditions, including but not limited to express or implied statements regarding the current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our development plans, our preclinical and clinical results and other future conditions. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "would," "should" and "could," and similar expressions or words, identify forward-looking statements. Any forward-looking statements in this presentation are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this presentation, including, without limitation, risks relating to: (i) the success and timing of our ongoing clinical trials, (ii) the success and timing of our product development activities and initiating clinical trials, (iii) the success and timing of our collaboration partners' ongoing and planned clinical trials, (iv) our ability to obtain and maintain regulatory approval of any of our product candidates, (v) our plans to research, discover and develop additional product candidates, (vi) our ability to enter into collaborations for the development of new product candidates, (vii) our ability to establish manufacturing capabilities, and our collaboration partners' abilities to manufacture our product candidates and scale production, (viii) our ability to meet any specific milestones set forth herein, and (ix) uncertainties and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Except as required by applicable law, we do not plan to publicly update or


For further information regarding the risks, uncertainties and other factors that may cause differences between our expectations and actual results, you should review the "Risk Factors" section of our Annual Report on Form 10-K filed for the period ended December 31, 2020, our Quarterly Reports on Form 10-Q and other subsequent filings with the Securities and Exchange Commission.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this presentation, we have not independently verified, and make no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source.

PRAXIS

Leveraging genetics to efficiently translate insights into therapies repeatedly






D2 Translational tools to inform development

03

Efficient, rigorous clinical development paths to PoC




Patient-guided development strategies





Broad portfolio of highly differentiated programs across multiple CNS disorders




* PRAX-222 is a collaboration with Ionis Pharmaceuticals, and RogCon Inc; Ionis is eligible to receive double-digit royalties on net product sales worldwide.


- ** SCN2A-LOF is a collaboration with The Florey Institute; collaboration includes 2 additional ASOs with undisclosed targets
- * Phase 2b trial in women with menopausal & mood symptoms

PRAX-114 Phase 2 trials for ET and PTSD, PRAX-944 Phase 2 trial for PD and PRAX-562 trials for SUNCT/SUNA/TN and for DEEs have not initiated Prevalence based on internal estimates

Six placebo-controlled trials across three clinical programs by end of 2021



PRAXIS



* Plans for upcoming PRAX-114 Phase 2b study in women with menopausal and mood symptoms to be disclosed by end of 2021

PRAX-114 GABA_A Receptor PAM

PSYCHIATRY & MOVEMENT DISORDERS

Depression Post-traumatic Stress Disorder Essential Tremor

KEY UPCOMING MILESTONES

1H 2022 Ph 2/3 Monotherapy MDD Aria Study Topline


1H 2022 Ph 2 MDD Dose-Ranging Acapella Study Topline

> 2H 2O22 Ph 2 PTSD Topline

2H 2022 Ph 2 ET Topline




PRAX-114 monotherapy MDD Phase 2/3 Aria Study topline data expected 1H 2022





PRAX-114 MDD Phase 2 Acapella Study topline data expected 1H 2022



PHASE 2

Dose-ranging study to evaluate safety and efficacy of PRAX-114 at doses of 10, 20, 40 and 60 mg

KEY INCLUSION CRITERIA


Ages 18-65 HAM-D17 ≥ 23 At least one prior episode of MDD Inadequate response to treatment in current episode of at least 12 weeks

KEY EXCLUSION CRITERIA

Treatment-resistant depression



PRAX-114 PTSD Phase 2 study expected to initiate in 4Q21



TOPLINE DATA EXPECTED 2H22


To evaluate safety, tolerability and efficacy of PRAX-114 for treatment of adults with PTSD

KEY INCLUSION CRITERIA


Ages 18-65 CAPS-5 ≥ 30 PTSD diagnosis with duration of >6 months



PRAX-114 ET Phase 2 study expected to initiate in 4Q21







MOVEMENT DISORDERS

Essential Tremor Parkinson's Disease

KEY UPCOMING MILESTONES

Q4 2021 Ph2a ET High Dose Cohort Preliminary OL


> **1H 2022** Initiate Ph2 PD Trial

2H 2022 Ph2b Essential1 Study Topline



PRAX-944 Phase 2a high dose cohort preliminary results expected in 4Q 2021

PART B: Open-Label Titration & Randomized Withdrawal Study Up to 120 mg



To evaluate safety, tolerability and efficacy of PRAX-944 in patients treated up to 120 mg per day

4Q21

Preliminary open-label safety, tolerability and efficacy results


1H22

Complete open-label and placebocontrolled randomized withdrawal results



Enrollment has initiated for PRAX-944 ET Phase 2b Essential Study

Randomized, double-blind, placebo-controlled study in ~112 participants



TOPLINE DATA EXPECTED 2H22

Dose-ranging study to evaluate safety, tolerability and efficacy of PRAX-944 for treatment of adults with ET

KEY INCLUSION CRITERIA

Ages 18 or older Diagnosis of ET for at least 3 years TETRAS UL score ≥10





RARE DISEASES

Adult Cephalgias Pediatric Epilepsies (DEEs)

KEY UPCOMING MILESTONES


Q4 2021 Initiate Ph 2 Adult Cephalgias Trial

1H 2022 Topline Ph 1 ASSR Biomarker

> **1H 2022** Initiate Ph 2 DEE Trial



PRAX-562 well tolerated in Phase 1 healthy volunteer study





PRAX-562 development strategy in rare cephalgias and pediatric epilepsies

